Science News
Discover the news and inspiring materials from the world of biotechnology.
The power of antibody-drug conjugates revealed in recent cancer trials
A new treatment combination containing antibody-drug conjugate called enfortumab vedotin, doubled the survival of patients with metastatic bladder cancer compared with the standard chemotherapy.
Learn more
A case to remove redundant trials of biosimilars reaches FDA
The calls to reduce the scope of clinical trials of biosimilars are slowly reaching regulatory agencies. The FDA has just announced a new initiative to make trials more effective and useful, which, among others, will discuss the usefulness of confirmatory clinical studies of biosimilars.
Learn more
Remote FDA inspections: new guidance released
The FDA has recently published a new draft guidance describing the remote oversight tools used for pre-approval evaluation of manufacturing facilities. The published regulations are expected to reduce the time to approval and facilitate the availability of innovative, generic and biosimilar drugs. The introduced oversight tools will also help agency to stay operational during the […]
Learn more
Popular obesity drug cuts the risk of heart attacks and strokes
Semaglutide (Ozempic) has been found to reduce the risk of cardiovascular events in obese people.
Learn more FDA approves first ustekinumab biosimilar
FDA approves first ustekinumab biosimilar Ustekinumab (Stelara®), a blockbuster monoclonal antibody originally developed by Janssen Pharmaceuticals, has just got a biosimilar counterpart. The new biosimilar, Wezlana®, manufactured by Amgen, received FDA approval in all indications of the originator, which include plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The FDA also granted it an […]
Learn more
Another win for antibody-drug conjugates in breast cancer
Sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2 antigen, was reported to increase survival in HR-positive, EGFR2-negative breast cancer.
Learn more
Updated Novavax’s COVID vaccine effectively neutralizes…
Novavax’s vaccine for 2023-24 season induced neutralizing responses against newly emerging subvariants EG.5.1 and XBB.1.16.6. in in vivo models.
Learn more
Market welcomes the arrival of new RSV vaccines
The FDA has approved novel vaccines preventing the grave complications of RSV infection.
Learn more